Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2011 (2011), Article ID 232435, 10 pages
http://dx.doi.org/10.4061/2011/232435
Review Article

A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen

Department of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands

Received 31 March 2011; Accepted 17 May 2011

Academic Editor: Federico Coluccio Leskow

Copyright © 2011 Renée de Leeuw et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [43 citations]

The following is the list of published articles that have cited the current article.

  • Rene Houtman, Renee de Leeuw, Mariska Rondaij, Diana Melchers, Desiree Verwoerd, Rob Ruijtenbeek, John W. M. Martens, Jacques Neefjes, and Rob Michalides, “Serine-305 Phosphorylation Modulates Estrogen Receptor Alpha Binding to a Coregulator Peptide Array, with Potential Application in Predicting Responses to Tamoxifen,” Molecular Cancer Therapeutics, vol. 11, no. 4, pp. 805–816, 2012. View at Publisher · View at Google Scholar
  • Kai Jiang, Zhihong Yang, Long Cheng, Shibin Wang, Kang Ning, Lei Zhou, Jing Lin, Hui Zhong, Lisheng Wang, Yang Li, Junjian Huang, Hao Zhang, and Qinong Ye, “Mediator of ERBB2-driven Cell Motility (MEMO) Promotes Extranuclear Estrogen Receptor Signaling Involving the Growth Factor Receptors IGF1R and ERBB2,” Journal of Biological Chemistry, vol. 288, no. 34, pp. 24590–24599, 2013. View at Publisher · View at Google Scholar
  • Liane M. McGlynn, Sian Tovey, John M. S. Bartlett, Julie Doughty, Timothy G. Cooke, and Joanne Edwards, “Interactions between MAP kinase and oestrogen receptor in human breast cancer,” European Journal Of Cancer, vol. 49, no. 6, pp. 1176–1186, 2013. View at Publisher · View at Google Scholar
  • June Y. Hou, Alicia Rodriguez-Gabin, Leleesha Samaweera, Rachel Hazan, Gary L. Goldberg, Susan Band Horwitz, and Hayley M. McDaid, “Exploiting MEK Inhibitor-Mediated Activation of ER alpha for Therapeutic Intervention in ER-Positive Ovarian Carcinoma,” Plos One, vol. 8, no. 2, 2013. View at Publisher · View at Google Scholar
  • Kathleen A. O'Leary, Fatou Jallow, Debra E. Rugowski, Ruth Sullivan, Kerstin W. Sinkevicius, Geoffrey L. Greene, and Linda A. Schuler, “Prolactin Activates ER alpha in the Absence of Ligand in Female Mammary Development and Carcinogenesis in Vivo,” Endocrinology, vol. 154, no. 12, pp. 4483–4492, 2013. View at Publisher · View at Google Scholar
  • Marjolein Droog, Karin Beelen, and Sabine Linn, “Tamoxifen resistance: From bench to bedside,” European Journal of Pharmacology, vol. 717, no. 1-3, pp. 47–57, 2013. View at Publisher · View at Google Scholar
  • Young-Hoon Lee, Heung Joo Yuk, Ki-Hun Park, and Young-Seuk Bae, “Coumestrol induces senescence through protein kinase CKII inhibition-mediated reactive oxygen species production in human breast cancer and colon cancer cells,” Food Chemistry, vol. 141, no. 1, pp. 381–388, 2013. View at Publisher · View at Google Scholar
  • X. Alexi, W. Zwart, R. de Leeuw, S. Canisius, K. Flach, C. Bentin Toaldo, J. Neefjes, and R. Michalides, “PKA phosphorylation redirects ER alpha to promoters of a unique gene set to induce tamoxifen resistance,” Oncogene, vol. 32, no. 30, pp. 3543–3551, 2013. View at Publisher · View at Google Scholar
  • Ming Chen, Guo-Jun Zhang, Yu-Kun Cui, Wen-He Huang, and Kwan Man, “Phosphorylation of estrogen receptor alpha at serine 118 is correlated with breast cancer resistance to tamoxifen,” Oncology Letters, vol. 6, no. 1, pp. 118–124, 2013. View at Publisher · View at Google Scholar
  • Jamunarani Veeraraghavan, Ying Tan, Xi-Xi Cao, Jin Ah Kim, Xian Wang, Gary C Chamness, Sourindra N Maiti, Laurence J N Cooper, Dean P Edwards, Alejandro Contreras, Susan G Hilsenbeck, Eric C Chang, Rachel Schiff, and Xiao-Song Wang, “Recurrent ESR1–CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers,” Nature Communications, vol. 5, 2014. View at Publisher · View at Google Scholar
  • Yang Liu, and Zhenjun Hu, “Identification of collaborative driver pathways in breast cancer,” Bmc Genomics, vol. 15, 2014. View at Publisher · View at Google Scholar
  • Rubi Viedma-Rodriguez, Luis Baiza-Gutman, Fabio Salamanca-Gomez, Mariana Diaz-Zaragoza, Guadalupe Martinez-Hernandez, Ruth Ruiz Esparza-Garrido, Miguel Angel Velazquez-Flores, and Diego Arenas-Aranda, “Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review),” Oncology Reports, vol. 32, no. 1, pp. 3–15, 2014. View at Publisher · View at Google Scholar
  • D Sengupta, D K Bhargava, A Dixit, B S Sahoo, S Biswas, G Biswas, and S K Mishra, “ERRβ signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells,” British Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  • J Cui, M Bi, A-M Overstreet, Y Yang, H Li, Y Leng, K Qian, Q Huang, C Zhang, Z Lu, J Chen, T Sun, R Wu, Y Sun, H Song, X Wei, P Jing, A Meredith, X Yang, and C Zhang, “MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells,” Oncogene, 2014. View at Publisher · View at Google Scholar
  • Purshotam Nainani, Aparna Paliwal, Neelu Nagpal, and Mayank Agrawal, “Sex hormones in gender-specific risk for head and neck cancer: A review.,” Journal of International Society of Preventive & Community Dentistry, vol. 4, no. Suppl1, 2014. View at Publisher · View at Google Scholar
  • Astrid M. Pedersen, Susan Thrane, Anne E. Lykkesfeldt, and Christina W. Yde, “Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor alpha,” International Journal of Oncology, vol. 45, no. 5, pp. 2167–2175, 2014. View at Publisher · View at Google Scholar
  • Stéphanie Bianco, and Nicolas Gévry, “Endocrine resistance in breast cancer,” Transcription, vol. 3, no. 4, pp. 165–170, 2014. View at Publisher · View at Google Scholar
  • A R Daniel, A L Gaviglio, T P Knutson, J H Ostrander, A B D'Assoro, P Ravindranathan, Y Peng, G V Raj, D Yee, and C A Lange, “Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes,” Oncogene, 2014. View at Publisher · View at Google Scholar
  • Padmanaban S. Suresh, Shao Ma, Antimo Migliaccio, and Guan Chen, “Protein-Tyrosine Phosphatase H1 Increases Breast Cancer Sensitivity to Antiestrogens by Dephosphorylating Estrogen Receptor at Tyr537,” Molecular Cancer Therapeutics, vol. 13, no. 1, pp. 230–238, 2014. View at Publisher · View at Google Scholar
  • Yue Wang, Xiu Long Niu, Xiao Qin Guo, Jing Yang, Ling Li, Ye Qu, Cun Xiu Hu, Li Qun Mao, and Dan Wang, “IL6 induces TAM resistance via kinase-specific phosphorylation of ER alpha in OVCA cells,” Journal Of Molecular Endocrinology, vol. 54, no. 3, pp. 351–361, 2015. View at Publisher · View at Google Scholar
  • Dan Tian, Natalia M. Solodin, Prashant Rajbhandari, Kelsi Bjorklund, Elaine T. Alarid, and Pamela K. Kreeger, “A kinetic model identifies phosphorylated estrogen receptor-alpha (ER alpha) as a critical regulator of ER alpha dynamics in breast cancer,” Faseb Journal, vol. 29, no. 5, pp. 2022–2031, 2015. View at Publisher · View at Google Scholar
  • Susann Busch, Andrew H. Sims, Olle Stal, Marten Ferno, and Goran Landberg, “Loss of TGF beta Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance,” Cancer Research, vol. 75, no. 7, pp. 1457–1469, 2015. View at Publisher · View at Google Scholar
  • Jihene Elloumi-Mseddi, Ikram Jemel-Oualha, Abdelhamid Beji, Bochra Hakim, and Sami Aifa, “Effect of estradiol and clomiphene citrate on Erk activation in breast cancer cells,” Journal Of Receptors And Signal Transduction, vol. 35, no. 2, pp. 202–206, 2015. View at Publisher · View at Google Scholar
  • Herbert M. Pinedo, “The 42nd David A. Karnofsky Memorial Award Lecture: Understanding,” Journal Of Clinical Oncology, vol. 33, no. 5, pp. 510–U184, 2015. View at Publisher · View at Google Scholar
  • Whasun Lim, Wooyoung Jeong, and Gwonhwa Song, “Coumestrol suppresses proliferation of ES2 human epithelial ovarian cancer cells,” Journal of Endocrinology, vol. 228, no. 3, pp. 149–160, 2015. View at Publisher · View at Google Scholar
  • Ting Zhuang, Jian Zhu, Zhilun Li, Julie Lorent, Chunyan Zhao, Karin Dahlman-Wright, and Staffan Strömblad, “p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells.,” Oncotarget, vol. 6, no. 41, pp. 43853–68, 2015. View at Publisher · View at Google Scholar
  • Sonja Thaler, Gitta Thiede, Jan G. Hengstler, Arno Schad, Marcus Schmidt, and Jonathan P. Sleeman, “The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer,” International Journal of Cancer, 2015. View at Publisher · View at Google Scholar
  • Atif Zafar, Sabahuddin Ahmad, and Imrana Naseem, “Insight into the structural stability of coumestrol with human estrogen receptor α and β subtypes: a combined approach involving docking and molecular dynamics simulation studies,” RSC Adv., vol. 5, no. 99, pp. 81295–81312, 2015. View at Publisher · View at Google Scholar
  • Zsuzsanna Suba, “The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance,” Drug Design Development And Therapy, vol. 9, pp. 4341–4353, 2015. View at Publisher · View at Google Scholar
  • Angeles C. Tecalco-Cruz, and Josué O. Ramírez-Jarquín, “Mechanisms that increase stability of Estrogen Receptor alpha in breast cancer,” Clinical Breast Cancer, 2016. View at Publisher · View at Google Scholar
  • Somchai Kritsanawong, Sukanda Innajak, Masaya Imoto, and Ramida Watanapokasin, “Antiproliferative and apoptosis induction of alpha-mangostin in T47D breast cancer cells,” International Journal Of Oncology, vol. 48, no. 5, pp. 2155–2165, 2016. View at Publisher · View at Google Scholar
  • Lufeng Zheng, Xiaoman Li, Xia Meng, Jinjiang Chou, Jinhang Hu, Feng Zhang, Zhiting Zhang, Yingying Xing, Yu Liu, and Tao Xi, “Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer,” Molecular and Cellular Endocrinology, 2016. View at Publisher · View at Google Scholar
  • N. Gonzalez, G.A. Cardama, M.J. Comin, V.I. Segatori, M. Pifano, D.F. Alonso, D.E. Gomez, and P.L Menna, “Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells,” Cellular Signalling, 2016. View at Publisher · View at Google Scholar
  • Atif Zafar, Swarnendra Singh, and Imrana Naseem, “Cytotoxic activity of soy phytoestrogen coumestrol against human breast cancer MCF-7 cells: Insights into the molecular mechanism,” Food and Chemical Toxicology, 2016. View at Publisher · View at Google Scholar
  • Mohammed Ferdous-Ur Rahman, Chunyan Zhao, Yumei Diao, Ani Azatyan, Jian Zhu, Karin Dahlman-Wright, and Peter G. Zaphiropoulos, “Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in breast cancer cells,” Oncotarget, vol. 7, no. 44, pp. 71580–71593, 2016. View at Publisher · View at Google Scholar
  • Sonja Thaler, Marcus Schmidt, Sven Roβwag, Gitta Thiede, Arno Schad, and Jonathan P Sleeman, “Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.,” Oncotarget, vol. 8, no. 42, pp. 72281–72301, 2017. View at Publisher · View at Google Scholar
  • Ting Zhuang, Na Yu, Anqi Li, Xuefeng Li, Xiumin Li, Gang Niu, Juntao Xu, Muhammad Sharif Hasni, Kun Mu, Hui Wang, Jian Zhu, Sifan Yu, Lichen Zhang, Huijie Yang, Xin Li, Yingxiang Hou, Zhenhua Liu, Yuanyuan Shi, and Weilong Wang, “SHARPIN stabilizes estrogen receptor α and promotes breast cancer cell proliferation.,” Oncotarget, vol. 8, no. 44, pp. 77137–77151, 2017. View at Publisher · View at Google Scholar
  • Joonwoo Park, and YoungJoo Lee, “Hypoxia induced phosphorylation of estrogen receptor at serine 118 in the absence of ligand,” The Journal of Steroid Biochemistry and Molecular Biology, 2017. View at Publisher · View at Google Scholar
  • Angeles C. Tecalco-Cruz, Issis A. Pérez-Alvarado, Josué O. Ramírez-Jarquín, and Leticia Rocha-Zavaleta, “Nucleo-cytoplasmic transport of estrogen receptor alpha in breast cancer cells,” Cellular Signalling, 2017. View at Publisher · View at Google Scholar
  • Lukasz Turczyk, Kamila Kitowska, Magdalena Mieszkowska, Kamil Mieczkowski, Dominika Czaplinska, Dominika Piasecka, Radzisław Kordek, Andrzej C. Skladanowski, Piotr Potemski, Hanna M. Romanska, and Rafal Sadej, “FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells,” Neoplasia, vol. 19, no. 10, pp. 791–804, 2017. View at Publisher · View at Google Scholar
  • Gary K Scott, Christopher C Benz, David Chu, Ravneet Kaur, Julia Malato, Daniel E Rothschild, Katya Frazier, Serenella Eppenberger-Castori, Byron Hann, and Ben Ho Park, “ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition.,” Oncotarget, vol. 8, no. 48, pp. 83432–83445, 2017. View at Publisher · View at Google Scholar
  • Ying Jin, Wenquan Hu, Tong Liu, Ujala Rana, Irene Aguilera-Barrantes, Amanda Kong, Suresh N. Kumar, Bei Wang, Pin Gao, Xiang Wang, Yajun Duan, Aiping Shi, Dong Song, Ming Yang, Sijie Li, Bing Han, Gang Zhao, Zhimin Fan, and Qing Robert Miao, “Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel,” Cancer Letters, vol. 419, pp. 233–244, 2018. View at Publisher · View at Google Scholar
  • Lufeng Zheng, Xia Meng, Xiaoman Li, Yan Zhang, Cheng Li, Chenxi Xiang, Yingying Xing, Yufeng Xia, and Tao Xi, “miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor–positive breast cancer,” The FASEB Journal, vol. 32, no. 2, pp. 588–600, 2018. View at Publisher · View at Google Scholar